The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Approaching sequencing in DLBCL in the era of novel agents
In this video, Evgenii Shumilov, MD, University Hospital Münster, Münster, Germany, discusses the importance of sequencing in diffuse large B-cell lymphoma (DLBCL) and outlines how to approach the management of patients in the second and third-line settings in the era of novel agents. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Right now we have a plethora of new agents, so the sequencing is very important. It is simple and at the same time complicated. So simple is that we have long-term data of CAR T-cell therapy, which confirms that we cure around 40-55% of patients. So we don’t have long-term data of bispecific antibodies or combination like STARGLO. So we can say that we need to wait to confirm that we can also cure a significant part of patients by STARGLO combination, I mean Glofitamab and Gem-Ox...
Right now we have a plethora of new agents, so the sequencing is very important. It is simple and at the same time complicated. So simple is that we have long-term data of CAR T-cell therapy, which confirms that we cure around 40-55% of patients. So we don’t have long-term data of bispecific antibodies or combination like STARGLO. So we can say that we need to wait to confirm that we can also cure a significant part of patients by STARGLO combination, I mean Glofitamab and Gem-Ox. So our strategy is to achieve as deep a remission as possible with novel agents and then to go to CAR T-cell therapy in the second line. So for instance that could be a STARGLO bridging to CAR-T in CAR-T eligible patients. In the third line we have substances like bispecific antibodies or antibody-drug conjugates like loncastuximab tesirine. So second line CAR-T cell therapy in CAR-T cell eligible patients, in CAR T-cell non-eligible patients, glofitamab and Gem-Ox. In third line either monotherapy with bispecific antibodies or Gem-Ox again if it was not used, GemOx with glofitamab if it was not used before, or loncastuximab tesirine.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
